Expression of class III b tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy

Electronic Journal of Oncology

Volumn , Issue 1, 2002, Pages 58-64

  Dumontet, Charles ^a,d   Isaac, Sylvie ^a   Souquet, Pierre Jean ^a   Bejui Thivolet, Françoise ^a   Pacheco, Yves ^a   Peloux, Nadine ^a   Frankfurter, Anthony ^b   Luduena, Richard ^c   Perol, Maurice ^a  

^a HOSPICES CIVILS DE LYON   (France)

^b UNIVERSITY OF VIRGINIA   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TUBULIN; BETA TUBULIN; CISPLATIN; DOCETAXEL; GLYCOPROTEIN P; PACLITAXEL; PROTEIN ANTIBODY; TAU PROTEIN; TAXANE DERIVATIVE; TUBULIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; FISHER EXACT TEST; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MALE; MICROTUBULE ASSEMBLY; MULTIDRUG RESISTANCE; PHENOTYPE; PREVALENCE; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL TIME;

EID: 0037871319     PISSN: 12928933     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Akerley, W., 3rd Paclitaxel in advanced non-small cell lung cancer : an alternative high-dose weekly schedule, Chest. 117: 152S-155S, 2000.
2. Miller, V. A. and Kris, M. G. Docetaxel (Taxotere) as a single agent and in combination chemotherapy for the treatment of patients with advanced non-small cell lung cancer, Semin Oncol. 27: 3-10, 2000.
3. Perry, M. C., Ihde, D. C., Herndon, J. E., 2nd, Grossbard, M. L., Grethein, S. J., Atkins, J. N., Vokes, E. E., and Green, M. R. Paclitaxel/ifosfamide or navelbine/ifosfamide chemotherapy for advanced non-small cell lung cancer: CALGB 9532, Lung Cancer. 28: 63-8, 2000.
4. Burris, H. A., 3rd, Hainsworth, J. D., Erland, J. B., Morrissey, L. H., Kalman, L. A., Hon, J. K., Scullin, D. C., Jr., Smith, S. W., and Greco, F. A. Phase II trial evaluating triplet chemotherapy using gemcitabine, paclitaxel, and carboplatin in the treatment of patients with advanced non-small cell lung cancer, Semin Oncol. 27: 9-13, 2000.
5. Wilson, L. and Jordan, M. A. Microtubule dynamics: taking aim at a moving target, Chem and Biol. 2: 569-73, 1995.
6. Horwitz, S. B., Liao, L. L., Greenberger, L., and Lothstein, M. Mode of action of taxol and characterization of multidrug-resistant cell line resistant to taxol. In: D. Kessel (ed.) Resistance to Antineoplastic Drugs, pp. 109-26. Boca Raton: CRC Press, 1989.
7. Rao, S., Krauss, N. E., Heerding, J. M., Swindell, C. S., Ringel, I., Orr, G. A., and Horwitz, S. B. 3′-(p-azidobenzamido taxol photolabels the N-terminal 31 amino acids of beta-tubulin, J Biol Chem. 269: 3132-4, 1994.
8. Dumontet, C. Mechanisms of action and resistance to tubulin-binding agents, Expert Opin Investig Drugs. 9: 779-88, 2000.
9. Sullivan, K. F. Structure and utilization of tubulin isotypes, Annu Rev Cell Biol. 4: 687-716, 1988.
10. Luduena, R. F. Are tubulin isotypes functionally significant ?, Mol Biol Cell. 4: 445-57, 1993.
11. Dumontet, C. and Sikic, B. Mechanisms of Action of and Resistance to Anti-Tubulin Agents: Microtubule Dynamics, Drug Transport, and Cell Death, J Clin Oncol. 17: 1061-1070, 1999.
12. Haber, M., Burkhart, C. A., Regl, D., Madafiglio, J., Norris, M. D., and Horwitz, S. B. Taxol resistance in J774.2 cells is associated with altered expression of specific β-tubulin isotypes, Proc Am Assoc Cancer Res. 36: 318, 1995.
13. Ranganathan, S., Benetatos, C. A., Colarusso, P. J., Dexter, D. W., and Hudes, G. R. Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells, Br J Cancer. 77: 562-6, 1998.
14. Kavallaris, M., Kuo, D. Y. S., Burkhart, C. A., Regl, D. L., Norris, M. D., Haber, M., and Horwitz, S. B. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes, J Clin Invest. 100: 1282-93, 1997.
15. Monzo, M., Rosell, R., Sanchez, J. J., Lee, J. S., O'Brate, A., Gonzalez-Larriba, J. L., Alberola, V., Lorenzo, J. C., Nunez, L., Ro, J. Y., and Martin, C. Paclitaxel resistance in non-small cell lung cancer associated with beta tubulin gene mutations, J Clin Oncol. 17: 1786-1793, 1999.
16. Dumontet, C., Duran, G. E., Steger, K. S., Beketic-Oreskovic, L., and Sikic, B. I. Expression of tubulin and multiresistance genes in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol®)., Cancer Res. 56: 1091-97, 1996.
17. Kreisholt, J., Sorensen, M., Jensen, P. B., Nielsen, B. S., Andersen, C. B., and Sehested, M. Immunohistochemical detection of DNA topoisomerase IIalpha, P-glycoprotein and multidrug resistance protein (MRP) in small-cell and non-small-cell lung cancer, Br J Cancer. 77: 1469-73, 1998.
18. Galimberti, S., Marchetti, A., Buttitta, F., Carnicelli, V., Pellegrini, S., Bevilacqua, G., and Petrini, M. Multidrug resistance related genes and p53 expression in human non small cell lung cancer, Anticancer Res. 18: 2973-6, 1998.
19. Giannakakou, P., Sackett, D. L., Kang, Y. K., Zhan, Z., Buters, J. T., Fojo, T., and Poruchunsky, M. S. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization, J Biol Chem. 272: 17118-17125, 1997.
20. Banerjee, A., Roach, M. C., Trcka, P., and Luduena, R. F. Increased microtubule assembly in bovine brain tubulin lacking the type III isotype of beta-tubulin, J Biol Chem. 265: 1794-9, 1990.
21. Lu, Q. and Luduena, R. F. Removal of beta III isotype enhances taxol induced microtubule assembly, Cell Struct Funct. 18: 173-82, 1993.
22. Derry, W. B., Wilson, L., Khan, I. A., Luduena, R. F., and Jordan, M. A. Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified beta-tubulin isotypes, Biochemistry. 36: 3554-62, 1997.-708